0001104659-21-135644.txt : 20211108 0001104659-21-135644.hdr.sgml : 20211108 20211108161028 ACCESSION NUMBER: 0001104659-21-135644 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 211388014 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2132215d1_8k.htm FORM 8-K
0001346830 false 0001346830 2021-11-08 2021-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 8, 2021

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
 (Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700
         

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 8, 2021, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2021. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)           Exhibits  

 

Exhibit No. Description

 

99.1Press Release dated November 8, 2021
104Cover page interactive data file (formatted as Inline XBRL)

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CARA THERAPEUTICS, INC.
   
  By: /s/ THOMAS REILLY
    Thomas Reilly
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

Date: November 8, 2021

 

 3 

 

 EX-99.1 2 tm2132215d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Cara Therapeutics Reports Third Quarter 2021 Financial Results

 

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) –

 

– Christopher Posner Appointed President and Chief Executive Officer Effective November 9th, 2021 –

 

– Conference call today at 4:30 p.m. ET –

 

STAMFORD, Conn., Nov. 8, 2021 – Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the third quarter ended September 30, 2021.

 

“I am excited to be joining Cara at a transformational point for the Company as it prepares for the commercial launch of KORSUVA injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients in the first half of 2022,” said Christopher Posner, Cara’s newly appointed President and Chief Executive Officer. “As Cara continues to develop Oral KORSUVA across multiple patient populations, I believe the Company is well-positioned to become the leader in the treatment of itch-dominant medical conditions such as atopic dermatitis.”

 

“In the third quarter of 2021, Cara made significant progress across our development programs, culminating with the FDA approval of KORSUVA injection for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “We are also making important clinical and regulatory progress with our Oral KORSUVA programs. Following recent guidance from the FDA, we aim to initiate Phase 3 programs with Oral Korsuva for the treatment of moderate to severe pruritus in both atopic dermatitis and non-dialysis dependent chronic kidney disease patients in the first quarter of 2022. Finally, I would like to welcome Chris as Cara’s new President and CEO. Having worked closely with Chris as a Cara board member, I am confident in his ability to lead the Company through its next phase of development as an early commercial-stage biopharmaceutical company.”

 

 

 

 

Third Quarter and Recent Developments:

 

Leadership Appointments

 

In November 2021, the Company announced the appointment of Christopher Posner as President and Chief Executive Officer of Cara Therapeutics, effective November 9, 2021. Mr. Posner joins the Company from LEO Pharma, Inc., the US affiliate of LEO Pharma A/S, a global leader in medical dermatology, where he was President and Chief Executive Officer. Mr. Posner succeeds Dr. Derek Chalmers, who will transition to a Senior Advisor Role to the Company.

 

KORSUVA Injection: Chronic Kidney Disease-Associated Pruritus (CKD-aP): Hemodialysis

 

In August 2021, the FDA approved KORSUVA injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, making it the first and only therapy currently approved by the FDA for treatment of this indication. The New Drug Application for KORSUVA injection received Priority Review by the FDA, granted to therapies that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications, and was supported by positive data from two pivotal Phase 3 trials and supportive data from an additional 32 clinical studies.

 

Following the FDA approval of KORSUVA injection, the Company has been collaborating with its commercial partner, Vifor Pharma, on the promotional launch of KORSUVA injection in the United States. In September 2021, Vifor Pharma and Cara submitted the required documentation to the U.S. Centers for Medicare and Medicaid Services (CMS) to secure reimbursement for KORSUVA injection. Vifor Pharma expects to initiate the commercial launch of KORSUVA injection in the first half of 2022, subject to CMS timelines.

 

In October 2020, Vifor Pharma and Cara agreed to an exclusive license to commercialize KORSUVA in the United States. That agreement features a Cara 60%, Vifor Pharma 40% profit-sharing arrangement in non-Fresenius Medical Care clinics in the U.S. Under the terms of this agreement, the Company received a $50.0 million common stock investment from Vifor in October 2021 at a 20% premium to the 30-day trailing average price of the Company’s common stock for achievement of U.S. regulatory approval of KORSUVA injection. In addition, the Company is eligible to receive up to $240.0 million upon the achievement of certain sales-based milestones. Under another existing agreement, Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) and the Company agreed to market KORSUVA injection to Fresenius Medical Care North America dialysis clinics in the U.S. under a Cara 50%, Vifor Pharma 50% profit-sharing arrangement. In October 2021, the Company received a $15.0 million cash payment based on the achievement of U.S. regulatory approval of KORSUVA injection.

 

In March 2021, the Company and VFMCRP announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for difelikefalin injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients. The EMA will review the application under the centralized marketing authorization procedure. If approved, difelikefalin would receive marketing authorization in all member states of the European Union (EU), as well as in Iceland, Liechtenstein, and Norway. The EMA is expected to render a decision on the EU MAA in the second quarter of 2022.

 

2

 

 

Oral KORSUVA: Atopic Dermatitis (AD)

 

In April 2021, the Company announced top-line results from its Phase 2 KARE dose-ranging clinical trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients. While the study did not meet its primary endpoint, in a pre-specified analysis of mild-to-moderate (BSA <10%) AD patients (64% of ITT patient population), the study met its primary endpoint of WI-NRS change and secondary endpoint of 4-point responder analysis in this patient population. Additionally, a statistically significant improvement was demonstrated in the 4-point responder analysis, which we expect will be the Phase 3 registrational endpoint, in mild-to-moderate AD patients, with 32% of KORSUVA-treated patients achieving a greater than 4-point reduction vs. 19% in placebo group (p=0.03). Oral KORSUVA was generally well-tolerated across all doses.

 

In the third quarter, the Company held an End-of-Phase 2 Meeting with the FDA to discuss the results from its Phase 2 KARE dose-ranging clinical trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in atopic dermatitis patients. Based on meeting guidance, the Company plans to initiate a Phase 3 program in AD patients in the first quarter of 2022.

 

Oral KORSUVA: Non-Dialysis Dependent (NDD) CKD-aP

 

In April 2021, the Company held an End-of-Phase 2 Meeting with the FDA to discuss the results of the Phase 2 trial of Oral KORSUVA in NDD CKD-aP and the potential Phase 3 program. Based on meeting guidance, the FDA indicated the acceptability of Stage 5 pre-dialysis CKD patients as a viable patient population for a Phase 3 trial.

 

In November 2021, the FDA provided written guidance indicating the patient population can be expanded to include the group of Stage 4 pre-dialysis patients with advanced CKD in a registration program consisting of two pivotal Phase 3 clinical trials. The Company expects to initiate this registration program in the first quarter of 2022.

 

Oral KORSUVA: Chronic Liver Disease-Associated Pruritus (CLD-aP): Primary Biliary Cholangitis (PBC)

 

The Company is currently conducting a Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with hepatic impairment due to PBC. The trial is evaluating the safety and efficacy of Oral KORSUVA (1.0 mg tablet, twice daily) versus placebo for 16 weeks. The Company continues to screen patients in this ongoing Phase 2 trial and, primarily due to the ongoing effects of the COVID-19 pandemic on patient enrollment, currently expects to report top-line data in the first half of 2022.

 

3

 

 

Oral KORSUVA: Notalgia Paresthetica (NP)

 

The Company initiated a Phase 2 trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in patients suffering from NP, a nerve disorder characterized by chronic pruritus of the upper back, in early 2021. The Phase 2 trial remains on track to be fully enrolled by year-end.

 

The Phase 2 multicenter, randomized, double-blind, placebo-controlled 8-week study is designed to evaluate the efficacy and safety of Oral KORSUVA for moderate-to-severe pruritus in approximately 120 subjects with NP. Subjects will be randomized to receive Oral KORSUVA 2.0 mg twice daily versus placebo for 8 weeks, followed by a 4-week active extension period. The primary efficacy endpoint is the change from baseline in the weekly mean of the daily 24-hour WI-NRS score at week 8 of the treatment period. Secondary endpoints include change from baseline in itch-related quality of life scores and a change from baseline in itch-related sleep disturbance subscale at the end of week 8.

 

COVID-19 Impacts and Business Operations

 

Due to the ongoing COVID-19 pandemic and in accordance with the FDA’s updated guidance for conducting clinical trials, the Company has implemented numerous clinical and operational measures to prioritize the health and safety of patients, employees and study investigators and minimize potential disruptions to its ongoing clinical studies. The Company is working closely with its clinical and commercial manufacturing partners to continue to ensure sufficient supply of KORSUVA is available for the commercial launch of KORSUVA injection and its ongoing and planned clinical trials.

 

Upcoming Meeting Activities

 

The Company expects to make presentations at the following upcoming conferences:

 

·Stifel Healthcare Conference, November 15-17, 2021

·Jefferies Global Healthcare Conference, November 16-18, 2021

·Piper Sandler Health Care Conference, November 30-December 2, 2021

·J.P. Morgan Healthcare Conference, January 10-13, 2022

·2022 Winter Clinical Dermatology Conference – Hawaii, January 14-19, 2022

 

Third Quarter 2021 Financial Results

 

Cash, cash equivalents and marketable securities at September 30, 2021 totaled $193.4 million compared to $251.5 million at December 31, 2020. The decrease in the balance primarily resulted from cash used in operating activities of $58.8 million, partially offset by proceeds of $1.3 million from the exercise of stock options.

 

For the three months ended September 30, 2021, net loss was $1.0 million, or $0.02 per basic and diluted share, compared to a net loss of $16.5 million, or $0.35 per basic and diluted share, for the same period in 2020.

 

4

 

 

Revenues: Revenue for the three months ended September 30, 2021 and 2020 was $20.3 million and $9.3 million, respectively. License and milestone fees revenue of $20.0 million for the three months ended September 30, 2021 was related to the milestone payments the Company earned from Vifor (International) Ltd. (Vifor) and VFMCRP that was allocated to the license fee performance obligation under the Vifor and VFMCRP agreements, as the variable consideration was deemed probable upon the regulatory approval of KORSUVA injection in August 2021. This included $5.0 million of the $50.0 million equity milestone investment under the agreement with Vifor. License and milestone fees revenue of $9.3 million for the three months ended September 30, 2020 was related to license fees earned by us in connection with the VFMCRP Agreement.

 

Research and Development (R&D) Expenses: R&D expenses were $15.5 million for the three months ended September 30, 2021 compared to $21.1 million in the same period of 2020. The lower R&D expenses in 2021 were principally due to a net decrease in costs associated with clinical trials and a $2.5 million milestone earned by Enteris Biopharma, Inc. during the three months ended September 30, 2020, partially offset by increases in stock compensation expense, payroll and related costs, and cost of compound sales.

 

General and Administrative (G&A) Expenses: G&A expenses were $5.9 million for the three months ended September 30, 2021 compared to $5.2 million in the same period of 2020. The higher G&A expenses in 2021 were principally due to an increase in stock compensation expense, consultants’ costs, legal fees, and insurance costs, partially offset by decreases in commercial costs.

 

Other Income, net: Other income, net was $0.1 million for the three months ended September 30, 2021 compared to $0.4 million in the same period of 2020. The decrease in other income, net was primarily due to a decrease in interest income and an increase in net amortization expense of available-for-sale marketable securities resulting from a lower yield on the Company’s portfolio of investments in the 2021 period.

 

Financial Guidance

 

Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing unrestricted cash and cash equivalents and available-for-sale marketable securities as of September 30, 2021, including the milestone payments received in October 2021 of $65.0 million from Vifor and VFMCRP, will be sufficient to fund its currently anticipated operating expenses and capital expenditures through 2023, without giving effect to any additional potential milestone payments or potential product revenue under existing collaborations.

 

Conference Call

 

Cara management will host a conference call today at 4:30 p.m. ET to discuss third quarter 2021 financial results and provide a business update.

 

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1480703. A live webcast of the call can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com.

 

5

 

 

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

 

About Cara Therapeutics

 

Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA injection was approved by the FDA for the treatment of moderate-to-severe CKD-aP in adults undergoing hemodialysis on August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in PBC and NP patients with moderate-to-severe pruritus.

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s ability to commercialize KORSUVA injection, including the timing of additional regulatory submissions and approvals, the Company’s ability to obtain and maintain coverage and adequate reimbursement for KORSUVA injection, the performance of our commercial partners, including Vifor Pharma, expected timing of the initiation, enrollment and data readouts from the Company’s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the Company’s product candidates, the potential for the Company’s product candidates to be alternatives in the therapeutic areas investigated, the Company’s expected cash reach, and the potential impact of COVID-19 on the Company’s commercial launch, clinical development and regulatory timelines and plans. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

Financial tables follow

 

 6 

 

 

CARA THERAPEUTICS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

(unaudited)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2021   2020   2021   2020 
Revenue:                    
License and milestone fees  $20,031   $9,257   $21,223   $22,377 
Collaborative revenue   -    -    706    - 
Clinical compound revenue   241    9    278    616 
Total revenue   20,272    9,266    22,207    22,993 
                     
Operating expenses:                    
Research and development   15,514    21,067    59,870    80,711 
General and administrative   5,882    5,219    17,898    15,187 
Total operating expenses   21,396    26,286    77,768    95,898 
Operating loss   (1,124)   (17,020)   (55,561)   (72,905)
                     
Other income, net   111    379    502    1,970 
Loss before benefit from income taxes   (1,013)   (16,641)   (55,059)   (70,935)
                     
Benefit from income taxes   -    132    -    436 
Net loss  $(1,013)  $(16,509)  $(55,059)  $(70,499)
                     
Net loss per share:                    
Basic and Diluted  $(0.02)  $(0.35)  $(1.10)  $(1.51)
                     
Weighted average shares:                    
Basic and Diluted   50,114,710    46,885,424   $50,031,615    46,803,659 

 

 7 

 

 

CARA THERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

 

   September 30,   December 31, 
   2021   2020 
Assets          
Current assets:          
Cash and cash equivalents  $22,991   $31,683 
Marketable securities   121,203    149,242 
Income tax receivable   697    1,507 
Other receivables   20,350    557 
Prepaid expenses   6,258    12,076 
Total current assets   171,499    195,065 
Operating lease right-of-use assets   3,310    4,279 
Marketable securities, non-current   49,221    70,565 
Property and equipment, net   654    840 
Restricted cash   408    408 
Total assets  $225,092   $271,157 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable and accrued expenses  $13,812   $16,881 
Operating lease liabilities, current   1,716    1,602 
Total current liabilities   15,528    18,483 
           
Operating lease liabilities, non-current   2,373    3,673 
           
Commitments and contingencies   -    - 
           
Stockholders’ equity:          
Preferred stock   -    - 
Common stock   50    50 
Common stock subscribed in Vifor stock purchase   3    - 
Additional paid-in capital   699,482    641,195 
Stock subscription receivable   (44,969)   - 
Accumulated deficit   (447,376)   (392,317)
Accumulated other comprehensive income   1    73 
Total stockholders’ equity   207,191    249,001 
Total liabilities and stockholders’ equity  $225,092   $271,157 

 

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT:

Janhavi Mohite

Stern IR, Inc.
212-362-1200
janhavi.mohite@SternIR.com

 

 8 

 

 EX-101.SCH 3 cara-20211108.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20211108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20211108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2132215d1_ex99-1img001.jpg GRAPHIC begin 644 tm2132215d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBN7U_5 M)T;RFU&UTNW/1II,2R>X4<@?D:F4N57+IP4GJTEW9TCSPQ'$DJ(>N&8"G(Z2 M+N1E9?53D5YU;Z%_:B/+INIVEZ5/SX8@Y_$>]4V74=%N\'S;:8?DW]"*YWB) M1UE'0]"G@*55?NJJ;_KYGJ=%8OA[7/[7MV650MS%C?CHP]16U71&2DKH\^K3 ME2FX2W045R7B+Q_I^AW#6D,37EVAPZ(VU4/H6YY]@#^%&QZCU%;U4FFKHI-/5 M!17,>*_&4/AB2WA%K]JFF!8IYFS8O0'H>IS^1JYX8\1Q>)=->Z2'R)$D*/%O MW8[@YP.H/IZTN97L+F5[&W117'>)O'G_ CNK?8?[-^T?NU??Y^SKGC&T^E. M4E%78W))79V-%>:_\+9_Z@G_ )-?_85L:%\1=.U>[CM+B![*>0X0LX9">PW< MER54B^IV5%%-DD2&)Y9&"HBEF8] !U-66.HKS^R^*,%UJ<-M)IAA MADE"><;C.T$XR1M_K7875Y>P7!2+3C/'C(=9<9]01C^M2II[$J2>QH444511 MC>*M8;0_#MS>Q?ZX )%QG#'@'\.OX5Y)X8TQ_%'BA([V6216S-<.22S >_N< M#\:]8\7:1)K7ANZM(/\ 7C$D8_O,ISC\>1^->4>$-6'A[Q/'+=AHHB&AGR"" M@/J/8@?E7/5^-7V,*GQ*^Q[?!!#:P)!!$D42#"H@P /I45]86^HVQ@N8PZGH M>ZGU![&IXY$EC62-U=&&593D$>H--GGCMXC)(V%'ZUK.48Q;GLCHBW%IQW,7 MP_X??2)KB66579_D3;_=SU/N>*L^)=1;2?#E]>H<21Q80^C$[0?S(J;3]1^V MO(C(%*\C![57\3Z>^J^&;^SC4M(\644=V4A@/S K##5J5:CST'=:EXBI.I)R MGN>;?#[P[!KFH7%Y?IYUO;XPC=)'.>OJ!CI[BO4WTC3)(3"^GVIC(QL,*XQ^ M5>7_ \\16VC7US97\GDPW)7;(_"HXSU] <]?:O6'NK>*W^T23Q)#C/F,X"X M^O2M*7+RG-2MRF3H_A72]#O;FZLH2KS8 #'/EKW"YYP3S6T2 "20 .I-9.E^ M)=)UF\N+2QNA)+#U&,!AZKZC/'_ZQ6;X_P!8_LKPU+%&V)[L^2G/(!^\?RX_ M$5I>*C=%W25T<%M;QUX]<;F%JS'G^["O3\_YM5CP/>R^'_&,NEW1V+.QMW!/ M'F G:?SR!_O4WP]8ZS9>&I-1T:WE>]O)O+61%!V1)U//'+G&>EHZ!JJ: MUH=K?J1ND3]X!_"XX8?GG\*\N^)G_(V?]NZ?S-:UG>%S6J[Q/09H?!MO,T,\ M6@Q2H<,CK"K*?<&O,/&1TH^)#_80C\K8H;[./D\S)^YCCIMZ=\UU7BOX?W%U M-J&L6UYYDK$RBV\K&1W ;/7'M6)\.H=(GUW9?QEKM?GM=S?)N'7C^]W'T]:B M=V^5JQ$[M\MK'K\/F>3'YN/,VC?CIG'-+90,3$L@MHR.R@_.W_H1^@%:U':-EU-*CLK(S;WPW-:>$ MK'6CN_TB5@ZX^ZI^X?QPW/N*]8\':P=:\-VUP[;IXQY,Q_VE[_B,'\:X;7(/ M%U^US86]AMT445TG0%<[KF@V=\YEN]-AO!C[^"L@'H64@D5T5%88BBZL M+*3B^Z_X.C#3JUOTV_,T4XQV12TRQ-G&S2$& M1^N.P]*OT45[N&P]/#TE2IK1$-W=V<9XB^'EEJ]P]W9R_8[ESN<;=R.?7'8_ M3\JYJ/X5ZJ9B);^S6+LR[F;\L#^==XNNW;:\VE?V-,"N',OGQX\HL5#XSG'! MXZ^U-/BFT!5=G[QM1-AY>\;@=Q7?CTXK1THMWL9.G%NY%X;\&:?X<_?(6N+P MC!G<8P/11V_4^]9_BWP=?^)=1CF6^AAMX4V1QLI)R>23]>/R%:T'B)[G6IM/ MAT]F2&8PO,9XQ@@ D["=Q&#V%16WBH3ZBEO)I\T4$EU):1W)=2K2+GC:#N&= MIYQ3Y%:Q7*K6-G3[*/3M.M[*'_5P1A ?7 ZUG^*-!7Q%HKV7F".4.LDY&T.06"?7:,U!=^*5L]4N+:2PF-M;S10RW M2NN%:0*5^7.XCYATIN-U8;2M8B\'^';WPW:W%K<7<<\,CAT" C:<8/7UX_*L MSQ7X&N?$.L_;HKR&%?*5-KJ2>,_XUMP>(GN=:FT^'3V9(9C"\QGC&" "3L)W M$8/84]O$<(A63[.^&U+^S\9'WM^W=]*7LU;E%R*UC:K@-6^'89C,F/++%0^,YY(/'7VIH\3Q/I4- MW':RR37%PUM!;*1ND=6(ZG@#Y2UTF^O=0TN>U M:S7<4WJXDX_A8=?R%6M(U&;4K5IIK,VQ#8&)5D5QZJR]1_6AP3=V#BF[FA7! M:O\ #^YNO$/?G\:[VBE**EN.45+<1=VT;L;L5WEO+SG..<9_2NEHH YVW\,R6WB&;5$NK4B6'5;@79O1>*0H$8(/ *YR<+E>O?\*OQ^&K'^W[K6+B*.>XE='B+I MS#M0+P<\],].*V:*+@<[;^&9+;Q#-JB75J1+.92KV2F5Y@N1$#M+,Q*E<\C#$'D5T-%(#'CT M[5GTZ[BNM7!N9P-CQ6ZA(?8*<[@>^3],=:;X?T*31VNY)9H6>Y96,=O#Y428 7&,A XML 7 tm2132215d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2021-11-08 2021-11-08 iso4217:USD shares iso4217:USD shares 0001346830 false 8-K 2021-11-08 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 08, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2021
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2132215d1_8k.htm cara-20211108.xsd cara-20211108_lab.xml cara-20211108_pre.xml tm2132215d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2132215d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2132215d1_8k.htm" ] }, "labelLink": { "local": [ "cara-20211108_lab.xml" ] }, "presentationLink": { "local": [ "cara-20211108_pre.xml" ] }, "schema": { "local": [ "cara-20211108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20211108", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2132215d1_8k.htm", "contextRef": "From2021-11-08to2021-11-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://caratherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2132215d1_8k.htm", "contextRef": "From2021-11-08to2021-11-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-135644-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-135644-xbrl.zip M4$L#!!0 ( $V!:%/99O)%2@, *H, 1 8V%R82TR,#(Q,3$P."YX M!!5;@&IF.!-)W!]!P&G(F1\T'1NN_BT>]9J M.>CD^,-[9'Z-CQBC01NB-1:B/BG$4@ MT9F(DP@TF(W\I#K:=P._AS!>0_<.>"CD;:Z0_"+F*>]?A MG\?.3NWA>:3C+Y]ZY+EV\SH87+SZL-/M*_WKV^[E_4,[/[*AZ!/$!)F7P573 ML?45Y0WW7"$'WJ[O!][]9;N;X9P<6!]%C#]7P8/#PT,OVRVA"\A13T:E])YG MMWM$P5C9[+(5>,:5)IS.X$,])DR#][U\-:P%ZE)$\-U4@NS"M-SJ,RS( M.Q-F?#B(A4TG7UHUHYWIA=!GG&6'%CT6(&P[*K6%FF5&:7CSX"F)5$%XS8^S M=2)!&5Y61=L$"F(!64*B)*)IM!EGDDHEI0B4MS6YO[*/.M!'6?_5K2^:CF)V M CI%[$E"O^G8*\7E:_II2G.-8TJ(E5[1?]G-S]]&<7 I021=4%F8#T9$)" U M,^:=&@)YZDQ;^LW4,HQSD_8N2(]+;M&1#@>@_UMJV^M-%%HWB33JE>)[O MIH8I5TB-^$)[KIJ>^=QO"YI)K:#8)USRL WA8->,&7>DPDFFFR0QN8'-DBAY M6R2QP"3]CK)K#RB[#D&K+S*XD>1%J5D3=FL_CYV#Z=3&N+?&9> M>*BE9X4\+CCF9EQ+1M>SRC3S*B=:KQQ:KP2U-R:S72);9S%C/BI2KN7KYJZ= M)I8/;_'+_!^4M:Q2DG*;V+\L;\M@6\LNYK'FQ88QW&"+9#LS"XRGF1A;#9)8\]LVT6QH"7&$4*3 24G]K\O M*8FR1/%(2HJ2S$5&([Z'>BD^(:D/4A]_VFTH>B$B33C[-)H>'8\081&/$[;^ M-/JZ&%\L9O/Y"*499C&FG)%/(\9'/_WXYS\A^?/Q+^,QNDH(C<_1%QZ-Y^R! M_X!N\(::8D(S*A./ Y^OYH>KQ"X_& M?+\1%G/Q]7Y>Y?N89<_I^63R^OIZQ/@+?N7B*3V*^&98AHL,9]NTRNUX=US^ M%.$?:<*>SM6O%4X)DN>+I>>[-/DT4LL3%>G)R?#R=_//7ZT7T2#9X MG#!UWB(RTE$J%UO<].SL;)*G:FE+N5L)JH]Q.M%VJIQE:M*AKSE)D_,TMW?- M(YSEU=Y[& 0JU/_&6C96N\;3D_'I]&B7QB-]\O,S*#@E]^0!Y<4\S_;/$J4T M422,RGV/@CS8S5 A)BI^PL@:9R16!SI3!YK^71WHNW+W-5X1.D)**?D RW76 MR*L,FK@V>T=$PN-+]C[79K0G^_)O1V3_0P'J\E:Y/_%=M:V_.;3:S^O5.V\EEL-BV27R0Z,Q-JDRJ*C!7%^;3R)(^,8TIY870[K"(>HI8*B81EQW45#=UM]!9*AUMJ%2H@15A MXZ^+T8^Y!OVN5?_Y.#GDXJRZY7!HNR$L6\I\+>5H)KNJ;)LI7=?UM""JVF+( MK&DM04KCI9HOY.%C9>&*XK6E$$:ZJXJVVM(UW4@,HJIMCLRZKC1(B?Q6]A>2 M1B)Y5L/\KM(T9,ZKWF*R14!-$Q8(;6,P#S6MUZ;^GJP3U>4H(^KJEZB='0T; MH'?=&73:-GL'JS@(=(8X!/N/>A"JHKS2=,'8%M-[\LQ%%T1-F6MV;"9-9.J: MH$BQ& ,!*;2H$'OEXA];>6U/!-WWHM%2NJ8#L&H"8LB"8L3N#<2DDH= RE)@ MEB:J2>M%I2UU?DD"F&U=GABZH&@!S,&7+94^!%X6CX12]10!L_[&Q29VS0QL MV*2FK0R*&] >2$X>@#F(&ECDFMXG0BW;7115XF!!,AT.9"D/ M0RK.*T^U!QD])+64KAD"K)KT&+*@N+%[ XDIY"C7AX+*)8L'@5+I_&!BV+1# M4HH"1*3IK \0J?:/QU621I@6CJ[DOK2CD!:M:TQ NR8J+6%0N$#N0&2* $U. M'A( -O\B6 R#IJ;T@TS+JAV82A8@+J:W/EB4WB,JLZT0#>]P'P1+G3WH[3%; M/?,%=$'@TF.N]22XD#=P\=HG7;(LR?;J?;V;[69%A*6(;8DK0B!SF@PS/0@B M %,F"84,*1TJA![K7S]M8)EZ51(LE"ESRX'=9).%IB8@'JS& "8.VOS-58]< MS&1;)3"=LYCL?B%[L'0MG5LR )M-- Q10&S8G0%PE&*4JY&4>\3C3B0;+/:+ M).KI/-I"MX! 1IN$F*J $ &L 8R4:K28S_SW+4N\F\<2VN0A*=Y#[V$%U+M% MIL=VDQQ '!! W0X!CF00:D;YQVG.(BZ>>>UUBAG?RB9Q/^,Q/'+IB7*+UJ B M- 'K# D(LR$^ =@:H1^*=UX05[.(\@R0RL$C=Q=Q+$]76OYSG3 R!<^"5>N6 ML0Z[3;(LPH!X@MT!%)7*#WH#J1ATR\)"Y^0-!3[QC\[)4'1.@D;GY#WH+%]Y M4.B2N6_-7V:CBH] ).VZH5FX,L M/&A:WOJ040%JG*-"_,.2#[MNQ9W@+PF+X $U)/>"#6#:RHZA#0\@N\$^BJKA MLH[SCU(Y<._]@]$R/RU.TZ2]N2DTX:'2--;;T!1J_V#<\33#]-_)<^OQ33M5 M!Z\3@JACTTVK^];I7NKT-Y%D\O@SOMEL6?G,R/:F(J!S5=>=-G6]6T5!,-#E MS.2AU**FV L<"TZ3*,D2MOY57JR*!-O*9A.YP@(VJ)EH*X( K1ETG 0(JWT M@L*=( I((JLCGZ:HEDH2MP\/UE% E]@5&OV&-2*P,@A4>NV9R,B <52+0$4( MRF-"@&>>IELBWH20)<032*!Y *>6/D2H().]:!6!_@E;D&@K^\W]]&2U3#)J MNPQM2YSU4H"YJH\RTH,@!#!E$I&G(?Z IB=_7?T-Z2@O$-SPIO.P&;2[!#JFB! Z##6NG II4AK_4V- M.'1EZ_[!P=K;X&#=,SA8AS@X6 \='*P]#P[TP8N%3F1+=;NBR1H#"S!VJEVC MT6'9I,0B#0H8V!_8?E0AZ!#C9^W.? $W]8$"L^[4 MK7?[7DZ/[>:K.8 X"*B&. 1>T%%!XR<5A718>?_,(T_?.-VR#(M\_KNPM5* MSBT_@,TF-X8H(%[LS@!.*C$JU#ZGDQ>K7U1#L.*+3& Q(;GCR>6=IHTYYE9M M0.1T&H1FG)=KEAQ&SD64UTF@&5%?TDA>R!>58Q:\ 9KLCPO?"-F9LFC*1PUV2HW!)AM=@DHB$)B B;+X"(7(JTUB,1EQLBUK+; M^UGPU^RQ7)46+"&@=DM(I^4F*59I0,1T^0/(T2&HB-$+"?M$:'=86+U83Q(N MKT7J&![0K$%.2Q<2-I"Y%C.41.K^S W/T)*CKRE!V2-!E^7G^^HKXA?Y^/T& M2Q2I"1K%R)W%6-A ZA([_QX+:+CU59:6,@B<>NW!7VBI(I .\<+.K>19U*_X M1?](:XX&FI>T]2G#X*I@29-LO*PYF5X'HA4I/^5F>I+_<,#P(;( M\;C98M 8-M<409 "VH(&S?4O)_A<&7"[HDET13F&[\HT-([7 VS;,Y8"/ @" MXJ#M"EH ,!>B7.F1@L^8/8GMB//0#*H)1+=KK-5QZ6.F0Q)_W]^2!"#4# M8DEVV6=YN*>.JY !L:ZO\ 87Q[S@ZPT, L6WNH4N!U-4SP"MU)MH91;H=Y4) MRG.Q?1N^ONM:;LG=>I?\M<(ID7O^"U!+ P04 " !-@6A3BC;V]EX' !' M60 %0 &-AIM])7PS!V1 M0\:IB@8R77)JJ/VB:+@?O6YU.].HV034^Y6*1*HO#Z-=O0MCEKK?;J]6JY:0 M3V0EU:-NQ3*%53@VQ&1Z5UMGW=G^%,4O.!./??=K2C2-+"^A^VO-+ANNW6VS MJ[.65/-VK]/IMO_Y=#N.%S0E328*EZV M<=8NW=G5;+]E ?L]3S3KZ]R]6QD3DX>]MIG(:^'^:Y9F37>HV>TUS[JMM4X: M)?RIP77R@ZNVPX M8]M*K]OM=MZX-EX=&)G-TG90S5S_:D3M@_:7BFHJ3"[YUAXX*$+7QG8KFI05 MN?:?ZZ%AQA7:=IYNU'0]+4MMF_9C8;EUJ'2)R_C "^XB(H\DE[T[YZYIW)K+ MIW9"F>7?Z[@/CD>GV>ENJ;^RA[[GS5U-M5$D-F5]G$PISUOY;FV.3-H_S;>2 MRL366^W:H<6Q9_N!O%)Q)%5"E>5>UD54?!"^TTZ[M6@OB;(5->,%X[O(SY1, M?8RV/*3'T7UI$X3X:7ZGNI8L:6C4X/W MP!)(N8=*N4(;"NSR;'J@<^:\=@ZYBS-U!\,CA:<($/\9YM@15(L:ARLA,L(? MZ%*J&OR'ED#JOV-2K]*&"OOOC"A#%=] >)\8 Y&_QD3N48A*?:*(T,Q1@F _ MM09R_P/UYL2C$17\>$$Y=XD@$: >7V4/A/\G)GR_SA>#_^;)W0/8"P\\ GM% M@$%X\U*"<*(6-0[W5#&9V,N^ D3@Q!C(_AR3O4?A"Z!^(Q(H\YTI.&O"1WXD M#Q7XD.F8\,*OH3VFP] KS*'@4?+56IDO /Z_E"@P^CUC*'B4%+9&(@KV0:;4 M@4O!<<9O#06/DKS6B40A?R,,,QLWQ_ Y2Z<_'LP>$C^U@I)&25A]HA )ET\L MA'$3*"'*QY90TBAY:D@<(NV!5:4('XF$KC_230CWB2F4-TI^&I2'"/Q>L92H MS9C%]\^#WX/#1\EA:V6^*/AGSX-_!H>/DL?6RL2'/[ ?[]1$KCSSWUYC M*'B4/+9&(C[V_#ITI^Z5?&+%^JTZ]B:D/X?VQ9=\]9;0\ECYCTAH3B/+0L^H![^.%;X'1D J6,DN=6RL$! MZZ*M*/%WY4,+*%:4Y+5*# K56^GF6192!)_TGEI!Z:)DH3Y1. .R6Q"MO8/! MWM?@-78HP^VQ#!28WQ0SUH^!3--,;)_X>.;A/*90R"BI8U >"O"QY"QFAHGY M)WM'J1CAU;2K[*"H41)%OS 4SO>*NJA3>[.>KS1S>RC4W6SF&Y%#]E#N*'EB MO="7P'^D=4;5<>?$"DH<)5WT MB4(A_%E.%''[$\>;="JY?\-+I2&4,TIR&)"&@OK FVK(1R90O"A98:44R>@\;D^3/'9)1LT2<*E7"QPMV>8W=3SN;$ MOULN6 "\?PB3>T JSD[%?$.3V]>NTMR;H?U0#=]C"L6.LR4T) \'>)8P0Y/" ML2$31,0V'=OMX//D]_6EH&' V3,*%(TXB?"-O*L_YX#&%@D>;A+C[ M2D#Q(TY>AL6BKJ SU'G.GNA[8LC6SU 4?"6@44"<35N4"IF"-8_]M,7._V"_"NLP>]J0(3O%8G[0I(X=@L[BJN] M2(CRL _90^FC;B3U"T7A?^?>?K9_IY6[-+(Y7VCY17TI:"Q04EVH:,PK[]Y[ M#8(7W@,[*'7$I+9*&.:.L&S*63SDD@3OXP_,H)01,]@*68B0KXEX5-G2Q)M[ M)6-*W52-WIU_@#0*6 $T,(BY[;-08#YPD&GJMDK)^'&\L-+U76;R-\5:+X./ M'8+EH '"W+0*$(YZIZ1_;&:CR?7F@\"]$;CXQOUR;[VU1_X'4$L#!!0 ( $V!:%/P0Q?'\A( M +AH 2 =&TR,3,R,C$U9#%?.&LN:'1M[3UM5^)*TM_GG/D/_;![=_5< M@80W!1WV(*(ROL WE&_>)JD@=:0,-T)+_[ZI[J30 )!4,&9NSOW121=755= M755=5=T=C_XS[AMH2!BGEODEIB:4&"*F9NG4['Z).78G?A#[3_'SIZ.>#7 M:_(OL9YM#PK)Y&@T2HS2"8MUDVH^GT^.!4S,!2J,(^%2BJ(F;Z\NFUJ/]'&< MFMS&ID:FG0QJ/BW'+UJGH&UFT!"H>.(322<74$.K/NL0!,XEW<80J!T)FG5! M;1^4)=U/:.T3&R.!*TY^.'3X)5:V3)N8=KPU&<"<:.ZW+S&; MC.VD:ZE)T2_IH3WZOW@KP(8:$XO%U>Z@V.U$.SAQGA#ZD'Z35=)%P^>PV>$\%+W<.57F!I*?*V MI4\0MR<&^1+K@!H6D*H,;-2B?0"Y)B/4L/K8W',?[ $#C':DPNMTZ/?3*1\8 M>%) IF42V4C'!:&YA F3D-^HKA-3&HCX"H#73A]P::[NC^V&\#"GS.H+78FK M*G@WVYK]'D,FC!I($5J(U(98<:8.1\D0B?=0=5WNEQBXZ4+; F>$3:DF07Y" M6A0KRO9(%I(A00B.P',2!DLZX2Z$<-,%+M=?8 W)1;70D]Y7V&7<-Z3$F.LQ MK]D&%_(EQFE_8!#7;7BDPLA=C.-F;M9H .N :9Q4;:BKS0(;%LLT/QZ&91$OK#I_CW:.![VCYF76H6 MD!*#Z&)0##=Z[CNSRGT?HBD: %4.D=#4.#9H%QYI8&6$!= '5I^&8Y!X'7?E M(AE< %Q\<=L: /W4P/8IQ-N6;5O] DJ+9R.JVSVQOBA_Q$+=VQ:#0;O=CPVL M/2' @;AE4/T0>8T^)K==G;6+4<3\#0TB&QK!- M^?$!-H.8?1X5P>11>\IG&[@4L%N?T';QYKK:JIR@9JO4JC1=RMLFV:R4;QK5 M5K721*7K$U2Y+9^7KL\JJ%R[NJHVF]7:]%IK7"%7Z81W%D%A7LG)6#<>/[$T1P0H(MMXT*9A M^2Q ?_ZKW[Z\?"Q??;V'".;=$5J07JQX$+^8#X>F*O^SY;\9(B!_4/-&Y;J% M&I5ZK='Z@($!S;K#N(--&]D6=-1$90"I:51K(#6[H^\BJX-:/2*:'$9M"@0K M8ZV'37!^)9C&1)F4PT;OF@@^/3SF"-;]Z'65+M42.VJIF8Q<#*R5-NT MP4#+;D&R;.E+M-#IG)04E3_?6.E-.!%1419)KDT&S!J*:0Y[D37X!']*##P" M__.BFMKZ3&C360T^?*4DCT.2/*4& ;+@V*+%5KN\.FEFGDL7ZS\;2Z MG\WETZO$ S_8ZPS0_VU+_D]J.[(8LD2I&SU"?,1U*B,HUREMD3@X7!JT/.E7 MU]"B+8ND;/7[E/./D( P,>1JT2\R^&JCB2K]@6%-"-OZ\,/6A*ZMQ$P*;["4 M2'%M[N&O9KNAPDH;:T]=!JN6'MQO<5@0$^:/N#,HVCT8 'RB4\.RV,K\X6,U(Q;2[\62,>*OF6MK0^9J,'(J*'&ZA!3PPJ^))2_H\X3S3W> MGIZ^7=-?'6=X:Q:R\MRY80M[[_DLM?%B![8Z]; M("7CG@Z69UE7YS:WGD][QK'F:O!&]2W$ .0..<@+%X4><-YO6EQ73\*.QX_( M[ <,]( .L('(F( 2T*%(^"'T('SWHV<\,O "<2$AK]U-1C^O97OKPWQ7. 5Z M*[NV%&.3?/GIFZ =\=I!7N@J\N>QQ?6B##NACT2RER MIGJ7[MJ5R7U^$S6#>9H0QBFY>'I?63B$LJ1D$%"'15WR"ECIU!\O*ZX'MR;8 MQZ";#BPIJWO%C=0-RSVB/2'(V1$>P'H([DWD\6UKC-K$L$:(=F3C*:R?Z"!^ M@3K4$!I/.:B_34R=Z&*OA-.^8]C8));#C0GBD(?QSD3V]#I8;; M-SVS7)2! M&BED&X0A;$[\MHYE ''13ZS15.30'.TP7UJ3 KH.S HF.2O EJ,ZK\S:L/TBQ*'8WIY M-U]24N3UJ_3-*)NKO3VB7^?06"1+[B0>'"[U'>&/%XPROP^"]6@ WT$B:!#8 M-A3'(5 FE?64V@YO%XI=PAUU'Y5/&RB55A( .+]0;]*Z?^MNQ*K6M RJP728 MW2OP=>#PC&C%I9V<:C5:ZKB!MZJXB_QL6&MG!$ _7 J+*JMF<%Q-!;0VM+,] MU=F,DG A?ZOM!ZEMR5/;.B/"MXGCI_(DB%A\6:W361:64:L_N*J77<(6RE#3 @/."D@_[>51NT6_B+LVD49<>+7(YQ1@:XW M@CBCW1[PG4UDQ$EC_ZE!.K.':Y[2%;^+FRQ@;8:L$K;$)2[W()G60YJ!.9\O MXRWA/7BB.<"_U^BQO*QYZ8%G7^[Y#QH^P[)JU)STVY;Q*XP\HWS,R*^]XU%R MWHGOI\!V1ST*3V8&OKFJ[CL%Y+6[HU]HW8C(9DMBWD]07)\W45-M:2K12V#K MNMMT2E0UM4T4"^=IBIV.?A^FIFE;VM,>#(JA(38<@OZI)!1%10-Q&:GWTFFF M%Y3YK=.Q88'[&:%GD:Y!1DO;2!^<43TW.*YM8M,Z1- ]SO@W%F-V3F_]"&3Y M&=&[^O6S<^N8ZC"UL2T]X4\6=_.B>(H5Q2'N:\QU_,/5;W2%V1.QT>5E^:5Y MV$[,=-1F*%E$55,7<1Y![0G29%46X)[ -1)YHFJN9$HY@CF (%&@ZJ(NLT9V M3X2+ U%&Q1SII$--]\BI6Y)2LGYP-%>/F\K#J0!Q6 M%8>[W)@SU8ZG(G!%'86?(A7QYZQ? &UB>V':>Q$FLB"\B"U[82"Q8F6)[+>7 M,H6/6"LQ((L!:S4MF=,XG$@HF!AOCT6\K8+*/,>]'2OF M0](R)H+XB )IH7TF, \MC PIAW[@ ["IB8(?UN1+' 2P>%6(CIG.W=T5?5E" ME=[!TX0J:-R)]73_/S%;<\5\4 @5N@&[_E MN1E9"1*' /_#$3400.O2D_'/XM"71C@K[\_FY*71Q6O 84_AWQE>(,\(?HJW M"1@A\#B0/ =)YI9,YFM)!F=@6\+_&U9'WE?75*D95G_W O&\2UOOO1V0U59M MTD>IA))*K,SE-TBU0;ACV/),4FU F%<@!,<."N/[_+(%:Y!H6.!L&Y'LA]Q4 MC!5KXH"W>SG/Q>W=T-M#93"*_ MJ8>[GS]14=?5$88%49SS8K <8UB"L6G"FJG) P\@ZMEBRCSABT58X(6(ENGH MAR.O=2%WR6X2B&]G7*85E\V$^[4$B_=@>MY!DOW\R:<+X7&;"*H=AYF4]]Q# M%G/AMICJZ:H\NVL@8O_*N$?;U'8IY?,)U>T.:,L.8Z*N[%WI!'!QLL.38_Q" M(!72"-RG -H0P$S??#+%%-3Z7W-:>O^0H(-!CQA <4/-FU(,F]SY]X M#QN&C-3:!-(L" #E]+2%>J4SAQUJ$%W^)M4#Z PL3J2A>I&5BTT]6#N'"JBN M#_#Y$T#X"CR]=S."H ]QI_T(A'R5,2AN4\-%+PEB6"5=1O9$<0ZYXZ&+PUFN M!-0$"/>\SN=/@DC HM3]0^Z=^N%N7+JFXB[9PK B#U%X2>N>4'?"<[Q7"ZWK&BT'4B9 OCEA] M(1WDC@:!MC>^+:K^_^0BFD\HZH!#$$[ M;H LY@+"J:I\22X2;\G=73H#FS;CEZM J4-(:M% MHEDBKFYMH3$4Z'ZE-]+%CF74$_/49<;D(NW>7Q-^Z\MO_W<-VLUJV?7 MI=9-8\4KZWZ!]+T>2M+%KLD/AS(O3E\O>]YS$]2Y_1;=,29(PX[8(Y'9O_L2 M*R_QY2 Q:+#9&8_>IL[]2GEZ!GO(NJ26FVQ^P-97=%.OAK+COB%8"%96G)K[M: MKK.?F@Y$TI>8V[\CYY\1.:<_-'+>XB[RG XGQ1\_D/FB^),;Q37_U,+!\8,\ MZ.)>\YW]B0;R=7SZJ"L7H\?25>\^W]T?'^D_'U>>A,>D=TZ\G6%5[WY[-^_OSXPIQ^C?=7&]4YI-^ MU\XU]IG^E1R;W99NGS>'CW\.;\X'SK?[_-68#T]/_DP_.IU4_^*^^W5RKO4N MSRI:;U"EMT]D?*J0)];_\<25U@]^892?>O>IP9VEUK63WI^UW%/J+,?NZS5Z MVFXU\3$NC\[__%8;/YY5,\II+4]K!]\Y'?TUPG3X[6QR=_ZDW![LEVO8Z/WU MO2/&'[>EEYNG7%\?]02P,$% @ 38%H4S[JT#DY+3$N:'1M[3UI<]NXDM]=Y?^ =259NXI21%VV MDXQK9I^V(!*R,*%(#0\[?K]^NQO@)4JV?$L*7]4\1Q()=#<: M?:&[\>5;[^1X;WWMR[?#3A?^,OS?E]Y1[_AP[\M']1=^_:A__K)_UOTWN^S] M^_CPMXV!YX:?F%D;AZPG1R)@I^*&77@C[AKJ"X-="E\.-N!%>/4\?B\4/\,* M=^25^XGY\FH8?F8C[E])^%C;V/NROW?X7%P[] MMK'QN.GF)48&5WBT]IEEJ6$)-Q0^T>" ^WQ]K3<4/A^+*)16P"[$V//#@/6& MTK?9_T;2W(&'@L@)@^ED>R20KX7U$!MNR;&'DVT/HVD $[YZ&$48/UM?XM M^UZ]K+*OGF?3O%T_NH)71M*5 2!"$&Y^[7:VF$83\5KB10(B F+>&'B4G7N! M"W]@ 3SI*OJ)0-KPTOH:TN)@*,6 '?X4%O#RM6!G@X&TX(7#P0#7#KXYA84; M]86OL-C]C:_93QDS4^-&AM7 M1U4%T6$/Q/$2HOQW%(1R<$M2[++7.?EZ=M$U$&NW:N J:_1VU**BH(JQ5#\4 M)9^A?CARK2K;/.6!S?_YQ XZ%YTM@W'6E\""W!]QBYX&&6AYHS%W;V&G6U$ MO C[SA;7PO'&TKVBK0E/C(2/ E/^![]S 4]K*$;T.BR9A$T=P$L!8"3L];70 M8[!4XAIE QO'H@%V?" M)DO+#$. M/1^D"DBX ,#7B^^Z7@0,8;-!(LA])<@)7 \&)/G!G?6U(:A,!]5F0*(L' KX M#S7"/UHC"->&D2YAILR&:M04O:M+QT8?'/N?R/M\Q/B(B9^61.D"Z]$7[&^0 M-4ANY!C<0)R!F'4#H,HHH1;)HX10!YHS0#^ ?3'VQ9@#G9.?4[9@#H<%&3)O M$.LBEJJ9A.R)3H''0"?@(HE*Z%4"X#8_PRBI7EE?NY'A$'A-Z9\?2O_82O^@ MBAEFE ,\)RUHT//E&'!5S:4R2R0<3YX ?X4(!\#HS* M8RF]OI:(:7:'E*XRO0:=0-':@@66;@24@X706XN=(;O'Q.*6[P4!&P$+R[$C M8DS8V!M'#BU.LJMA)1T)8\ NRZP08'\C'*+#DLDB!:. -/ CRF3 M6PH96L.*[8UP+X5L)&PM%5R;A@I8$,'2 @]PH!6L HR##!/*H*K)N;2;Q)TB M#Q2KF(H58#0;2(V"3<+B(H' 9KH"-@CB1?,B/UY4HBC]SD< D!4Y2%22<<3' M.!E8-,A18'@!D6?NESNV!U@(J=WUF.V1WP1=&/L'L#)W8"\#T.?#:ANQ&=X_I\(#6 8EE4J.NSPI7OT9][A!EDQ MAD?JXR1"4 %&#+W1)];&[_J>#\R8?+?O<.L',V'RP'.D#0 4'?AQF$7TRT>8 M<\KT?=@;/RI] 7L%8!P3S%F0VE,@0C ?.F6&,!^1,HH8B[B:LTW\?#0"=]N% MDEK=E,F#3\L4C\AB=TQ61C"4X]BW)7R6$ATP#O).MK(*, A$,*$L!('V6=CY?H05XY7A]-_L2BC$U&I>H\Q[NZ!74[1+4( ][P M8&[#>0)^M#PM(>R =>,?)LV5FR'H-XEQ ?1ER&!%[<)AI5T)NKMC7\L _EYX MCB#'-$.+Y7/N8(O%%M!1;"]^FA6>ZV3L&[037<&GR>V9FMBP M,S6]LG'/)SBD]QG)71:E!I%4AU?'8T;_0JP6'0QG.\IK" MD+!GT$"[$-<2!DAG-1A8R*X.)B@X,>83#GEH,#E( #64\0E@#7#_9OPFL/GQ MB5'6G@WX0,!L %4BVEPP^M?7"*O,"AE 9'[E>D1$>'SLPQ*YA!,\&@#3>+!. M&9\5Q(^KK#]?P0P6HFNCGL!82'N04"!IQNB2*$HK+QH=')N'7/L1-QX; MRVLO!$$7^PVA#PNK['K]/DJS]!V.#*$@@K<:]=3;"<+(!OHMGP1*W*WYG%DC M'Z8 NK&^H)5Q' X&:<8Y1KL_$U&"A0LI(O.G1*[5V@J#DS@@3#GR-%WOBCUI M/OON2A*#ER%L8G :071,!/R4],C.I305*N$@ZH]D&"HU#T[J/Y%$IK(]*T+> MY+'2H9GP3.. PM@J4'9"RA']7QA.?9 (B?"O0>>A0#ZYW%*.)&Q['%Z.^I$? MB.3TI8!5-0^G^#F&[X.<9SM_>(Y\LQG1,L0<'\.A 4P6 KL !R\CW\**GUFA MEUWOVJSUYE>^B,/8+@91G2C C0UB0[@!N=39B+C($#7#;2QFMMX0@ZTXIEI2 M$&D1AE&U]]RNO9\ I%E[CPP^D&$E@&](87 ?Q.^5&@&FP3#"5Q@$C!R0>R?: M #M /E,R)A&QQ)#?41\IB0HV6I HC02JO%V;Z /.WK5JU1H;@85%O()X [.# M60N^HW2O1:!/"5'<*21DD=*F"C?7"2\QDM$HWBZ-6@4C^F"\@<6)IPV@>-&S M&_M :Z:U@ 8KB5@H(-;7%!0X)[>&&!.-%2+AG DFW2FB2!K$8CI/!Z 0\/N5 M[#NTZ)HL+!KCIW?U9HXTT5C+I@E@P+ -.1 EX(X(*GV.1RSP$E#.PYVDUX:[ M'FI5X#;P&8@2Z=(HNLY8[@OA*HV$G', MMLP/$4X1F/#;C(E.0;T-60?8'KYC20QK&KN1^0,\JQB\56#P5H'!68:_:4$* M+#2;0\U6N@S,XL$0=,K&HK+F MRC(]C'QO+$#\$0^@S&>=*^%:MVSS\*0#K&7AV9QB)E\9B_C:"?$5+F@G"H=@ M2_Z'QZD&B1&Z>=*! 9 =@SIF',PZ1( MX2V?)+VM-PYQ; Y!X!T@(,AUX-ZL-9Q'4=G&L1R9-1;Z$0"8"JBBX0IJ)#&) MDX4!+8/$//R.Q[KJ^(<.ZEQV9 D'EM=@QU)8PQ!T5BBDJVQ=V,4W_#8E 8HX MLA_BI532"'QY2P9D7JO-<_B=P;)1=)L,=X&V=B$2O;B[9+[X:OTS.QN39_ ) MQ[U4_/B9_BX &[^%OY3!X>>)[62/N& =U %2-SU VNQTMY8V5 ,FG3-' M(-4;5]#%P*"$RN@@TQ*=0^5UU]D?G8M#<+X"44&3 <5GXE:30X[2*'=8^.!X M#\8TI6.G/X$M4SC-2]7)7T/I*)<+W7I40'C.AT?I8&(AY( Z4.D64TTH0FR0 MB$=;N!* [)4#B9:,J_44 J=G3PX:-_B&:9"&B3C)Y]K5M0_87G X%5V7@PY MV8 I:3)@5%DG"80XMQA%1K6&IBXF==W."A11:,8&)>Y22B!029N9!2@2\AGK M:S=#"<[NC=":3:GYOEJA.'0#AE^29DA)3)F5*5 _0VY#F1R-^ON,G5@AS@+H MDD51MJ;RW-@5_8H\"&H[A=R.E,E]#2QD[K['F<>@%$3?@S<\<#(VQ[^!A]'8 MJN;9&6D"IACF2^&)+*9]A)XC%'UT4@+:#[A%EM-3+R1EY*7%$*0\>N:'KEWQ M!A5:TO6U.IBJHIAK@2DW,K"B(-#1FU>6*NMK6;%REQC9YSK[;J3QB!,9\M@# MC[CY8 ^?3&2@Y-ON9/8 F-53TP>6CD,*FO+4*Q MDGKS.7:"]BOB?3"=V8&#@)A,D3*)*XR]$(/PF8BX9D#-S.1Z3^=F!$@?6>BX MJO(HXPP1 ."2/V^\XAT8B MHJZ4F,%ZXV.,&ORS)/\I/A+2P?HI% )]BXH1]"2G+%B2*I83V4I9*C64+$4S MOQ3),A"7LSQTX/= ,W4 MR6)W=54%7WSR>RQ!U=QW\'NL#W[/M?6WCX?\\/=@Z#FH\LC#.-\_6$X7(\LD M&)9,CE#1B$5+"\,LL90#KIA?IV?U=Y[GAP(_6VBQD/W+HM@+-I8F037D )AS'Z&XR*VUPZMUL,5CP H&*3 M$4$WVV .BA\36R:7?AQ8/IZ_Y4T#B>$E5YU7Y_4 A9&4NP"3QM@A O'SZN V M42,'9W\>=2OF+B.),@+B>,EL8&7[GN.HH':Z0)DM[5/-%IZ\*"]0G:7./*!: MX!T\7[RI48:6*+34*$-+KVPP@\*]DB /L: #-A?ZX6 OGZ^ [-=6@9U*^[Q- MN[[VE+A0(CB#"#-<4 *2*WEZCD$-<,HQ 00SSC F80VYSRW8.G1TT+]-3BK2 M7'XM-J/Q&)[OP[ZE"(3*;U8Y?;V"<>Z+$<>T/@S-^[C557W/(,)X@)*Q:KI; M&*<"SM "R\D[5C1&FJIBE @R&#CG6*KR'SI;\2+0BY4^: K; #];:<(*ZCM- M@YT*ZD,=_9)IB1I23"MD9>DF*I@"7SHK:8IQ< ]WT+G/3]"6H7! N9OU6IQ" MH2V&T_,JNTR_47&I%*?L*7-N[KHV!%(#8)K^WU'JWX /F*6CF("OKS45&;C* M'05Z"Y?.=K#PSK,5BR4QP9@22=!/*G]11P:)V_%@E?2S5LTXO(/Q1>[&AH " MLMZL#+%X0T47U]<"R\-4F)#> '@G\[P2D"X+P<<@<4UF04*%3+YP:/>#L1\[ MDHX<@,&%,ZM<+:#(7$,$CA!CW,UAY/?)HX+%#, S(0R(;3!S;Z"16;Y=AH7S ML;UV!.+3T@64^U& )[X!.XLK*9+]BDBC%O7 @8AOUD7'6H'.\DZ MB<8V<45:7@0[+N-<3+BM$X$:/)D=C1V*:L,@;C02/J4L9NN?,H6KN)<"3!.B M-*2QRLO$7",<=2BX@RYW3E:E$6H!$WFW0G.[%GZ4JR.O.-73XO=8:(]")Q/% M 5;W(W7^20XVFO6:;C&%E4+JR4RI$"7U95',)*7!HD8#X+F( MM*C.]PM4=I7R6$A,NT@&4K?2(B\"4RU1NF;S- "E:Q X% EZ8'DJK7\&4_R, M,5:7RI[RH8BEVP&PP[^/+:SMO$J"@AU4 U2RO92;>D8T:,1_H!+#U"65D1EH M(8W9)''.:A33PDJZ"F"QS4M1H-?9/SYD!X?'Q^>=;O?H]/??-FH;]/GRO',0 M?_[KJ-O[]MN&6:N]WW@L!/?Y9+V+>&0P&^C0+:8KO(@=9[[TNO$3-](.AZH3 MS,=>=V_*+]5Z2[KP\]>STUX6XLJ CT#K@]]W.^I[#M!C)&W;"X$B^&AAO.DL M.W/4.RFQL7<98JX-^T;"D5)NT]X1QD0,U6Q5S&VP&55/A0QP'WL7^'^X<,\> M""C9X379X5^"'#1XY'=5L#0?8[0KYD[)&*O,&.<2?>U+T/,._%5625>>1?57#43SS_"AS:&7+C7V"^@G^JQ4:M8C842]1+EEA) MEL"E97]A(QB?'<1^03J:U_^ M+GL);@>PD(8J*\#"KVONJ-0#-\X%)Y^3BK?(I\)4P5G=I& WA!SCDN_,W4:U MF18M9.H4W]5;9K65_,2Q,T!6\31,&JNF_&];6'Z<[(X^+]@Y%)M(CNSB/$IL MEH7!+D*$VGS!&SK>@$YOXA.BD_RNM5/=B4$PR#67E&SF#0:!"*E$$O/=L3(; M'S>KC03@I.F*^(G.M^K@094ZX+&KV,+RN=%?D\YAOA!L!&,/@YF-PY1A8# 7 M*.5@,AXF[+TSTR(5JF!]5ZO6ZDQ%_0,=AK*E$U'@<0C<8.38@J?#$<7;*8_$ MPS5:^>'6UR;&BP,C 1\)'6A%+B!N6MPEF>\DM5F>I-)):K,\27U137>T=X&5 MYQ'%C8[VF/Z4Z2V82HCUM3M["]*6Q\VG! 1LPE2*XD_O=M,O#,ITCGLG5MFQ M+D55@5Q=3,@&&//U-40H)NJY"L5I,-[=_I @BX]#="0]G4Z7V>7[BPCNN[&R M445_FT?(\ZX.;&^MKV&5(MND'[>R=6A4?(8S@J[QK.R<<>4M((B"BUH6(EM[ M?0=#VDF]%CVL9LW6M\6EE %52N$SUZ <47%C1:N+G4ETXIC*-X>';=1P?=+M M26'GO,6"E'X[T9D"U;5,CK!@<;-%B]Y I:GEBFW)W AO,_3.U-NFV*:%Q11P M)^3GYH_=K.)6W(&0S,D>M4GVR"Q3$#,"V KJ;!0([6KZ).H$Z,0X+K(;N M$@B!P$I+U<4XTZML\^(#'XT_=[?8X<\Q$B;XA,W!X0WU/86O\6MV@P?)6,C: MFER.AVS6O!EI5LUDL*3=1J+XZ?@DM2/QM-AG!;B4=6 J^,"F!'-^3(:@3@13 M5DG6"+6\()Q2H9D_1U&GL !CM;6^%L.8LFG*.8-W;*];6UU.U 0J*+F@*8)OWV)N@6Y7J#B?<#;T\5:@BK[A92^B M\SEG&8LP@*U_5R4FA%:V+?>U8)N_$Z-T,HR-;+V^IK^?9.Q6=??9^+I5K=_! MUBSF:C5$#^49=@ &YB[ =B]SNPE?L'NX I4(.%D<5(P^+XZ9PA%70$,4B(9* M]I1XGDG*2S\QC1_C':4%9W*.2:\L)3>=47<#V+?>2)!KI,PG];5,OU;MPL"; M,9^-8VH93_L.CBGXT]20 05"#KAB-BS/O44!(A!D&BDEZO*QM2'I.E(Y"+K^E(-C:$B4FK3@E_S,RJG MD,6,K6IHDSC6Y%.\BZ37Q]3.,FC&MK/&=,;SH""(LC&-)-LNDTD"FW<0Z?2/ M3,\U-Y2H"I &:80L41N*(F.))2OTI2U5/Y^X@2V U5!EHEX4LBNIRD!5GKS2 M*[?9MF!I^LT4W+'56?([K#HF&R46O'("DL7+]-1:["";2CQ+H^4'H/V69Y-1E*_QK@!N0)% M6S)*P2Y"58R9>8%VD?.MK_X;+>E^($/*//WR?>_FYJ:*W-?+-EP'>^/+Q^][ M"\P \\5R6V4LEV*YK3*6^Y)BI^,R#-N0:1'O<[ U@&M4Z;0R%Q([)^DC1E(_ MWHY] ?/0M2JYW'\J;,7,=Q %@U"'ZE!Z+/;FW-_K]-%H*?2>?B7U/&6=/K-' MSU+ 0DTK'W2% /4\?-;[D=BCKT>BTJ6@JI:'REE2,)CKP8?8- G%2QQ'Q!T MN#HRC(U'T%ZV1#N!@A,49FWAN'U4U4@%D!L4&#$C",7WD8&%*^A()9 M1=C[GIWQ.],;GK!$"A/?@]L _(%-S7"C@ITXXTOR-#%XR9.NFA]#90*-12F78:):-A>:HBW M"_@D8P:J= =^4';F8()H03*KMD.1*[0MBD5;<3<&K+KSP0*_&<8#)R%7F MYIA<[]VTFC/M.3T14M!!% RNI5YWYBR/VCL'01)'- -Q\5NV('61QS#;+7U])VC@G>.*ZN MBZ5YTCI\E7:"1?8@DVQ0_4&:P%,('NJB&-6N/E\6E"MZ2B(6:1,WQ&3F*PF< M@RA4+;#3UT)!7CT2T@<;W:C(ANH^9?8FIP*LI!6X+X,?ZCWLV4+8"X\N D"KV%>G')J_O(#ZSOCD0H-M[5-]G%06"0$P6WYHD7.AX/ Q;!]8 MONQC?U:L+U65T+!.10M0G\X,J-UTD)Y$7V83^ "SPY^Z1!0(KJ7#I%S1UYLA M%.PKH [N>W*SVE0O/EFTD:=<#5R8CNM&E"*)L7E<95!XHR2I^ ]]:(1;B(Y* MXJ;S =6BDDN(]@#@$Y^U B4'$0C28)CF3V2$^0SD-$D[CG,'W2E;XDZ=%8S! M^5276?"D)XA-5\F W49]^>";6W7FAG?K5=-;3',+I:RQD/\ D%TOF^@1>MAK MF\: M;"4 RT61Y[[D^?S".F) ;TRFS#<:[].UF)I4WVB^GW'5\B,"4^T[ E/39V], MS$X7V>=!SF:__X*QK6F1Q>_;X47G_/![[^C@TF!'IP?5Z:[4 M*X%T=MH]/+T\1)[I] Y/#D][E^SL*SL[!RA[1V>GEV\&W28?>5%R/.Y% 2A/ MK*__B9T*55:U,I^P33M]0E-ZZVU@C5P.M@G8EE/F?^:Y'E7F_ @Y.0_(&[1G M[Q"B"O*->&MG9-,0J%4)P-(&*%SO!FR/Z0'^@LB>(6D?.9[^XD:@3$1X'?LS MR#8;#7++\S/U5U<1Z9 M9]X2RTR;6DF;DF\6AF_F%F2?J:FW- M(^QTW=&G>Y9F!LEGD;GH:\[) /?X=L\_98E8B=CK(O:D+?X7FE53]G4L?' Z M['Q@8NN#Q!-J[A0#1M/ G%WM-2,>8TX+1-VU/+/?FP;/NUG33@F 35VP>LVH M-0I:[&% W!D.6W0"[((BV/Z%\:^;1KW>^)4)4#<:V\_( 2]MH,P09'- >9"F MK5^+.+=]<75)907UXRKBM%UKKR!63UVIUS1B[@5MAI.8-%=*BFCG$PH/\3GS MP>CY@V[SKN63!HY50/.1?ORC&6ZUZ+=;4N\IW+>]4]+O"?1KFP7]\QST>^5 MT]Q"NT=7>/VB@KIFU+?KY6YYBJPVZNT7V2^_# 7!8:S7"@YC2<*'D7!WMQ!T M>'.I/,\15 K+5K[&P74FA6 +&=FK%M%N*M"V80 M/'.@/=OAD>1L&68.R\2 M GN-^,T#0^W%SH2_V&J#C=78+6/&3R)AVZCOE"1\"@FWMXWM=BFVGW3VTWHI MS;=0 3J\NV=Q_9]-TS#KCW'%MQ89IVUC2L''DB/5:AFM]F,\U45&:KMN[-9: MCT>J/& KP[4E8JN&V)OK[QFF5N'6BE_,8C.+D=+2XGT _1K;9:SL2='&6AFM M?=+^-7:+ASAO[G ].DZVL7>,]Z*JME#PQQ4#&:H^@_H2GI#_O#<^]K;.5\TL M))XMN4EOMHUVL8)AR9$"YZO6*@CO)4=JNV;L-M[*^7I,\X-?PO@M$2L16Q#$ M%NKX:_^1^GW5C+A"*6AI C_$!&Z4+D3)?6]%O6;C5RD.K%=;N%*G(ISG &SF M^P]>:7J/V5[4=\3C.G8\==@[?;NI:,X%YWV.Q$J2L&VT:O>&S$H:/MQS+6GX M$!J"H]S7I0M6(K9JB+UZ5"RVL=)V]&4M8(E8B=CB[_9G#)%I(VN? M!W@MF6NSKG2B4-B_H+56J]Y_3%S:NW=3L'@L5%+P09YKU;SWH+VDX-T4;-V; M;/2Z'E=Y8OFK*?<2L65#['5"*G_1?1!X):Z^\I>\KK(%2XE8B=@2[/,7/?%: M(@_L >><#S?@6C7#-)O&]G/:P8\\,UX-@C;;QLY.RV@6J_56EZ OY5VTZ)X1 MHVT^HYN[Z+1\<>:L-8SV2^RWBXOLH[?>)N+K+?+BZR? M?<<4UT;QRD,F6?*+K/<[QYW3@T-V^>WPL/>&UU=GKZU>F%NI\S D3%5@J%6Z M57J^QFTS)=^T(0N*D[Z8>4-E"N>4ZS8?.<%T.?SPZX4?B,K24J8K+"*,FASL MSA>ASE/N5%XG>/[TMR_9*0MQ U>CK2O'DV: D\G M"$2XP+6J93SRK<\=IL%P$/D^;"G&B7O* X@E1>R-&@AK$WF[.=^]H@<\4$W& M+?P'.,WRFCO ?4M[VS#>^_(KWS:,(="=9[QM=\$:XY]P_X<(>=\1+!!6Y,M0 M+G(W"!,O/ZX]IAW$HLM(L[EKU)N%I+SE$))S0'F45",S'WP]$(O 7(EE;IO3RE570!:;NRVCUGY, MQZIED,>YIN&"!T*A7?$&E0@^+#K;-8Q&,==K!9@.UKK8MG,1!-$M!1 Q=DAW%,[31?DM/>76*MY2 MN--\JIQ>*'DVPWZ^$$'H2PO+-#!>_8L9X MKX-GL?N,9>.+G@W^8H0$Y],LALR>.0O\]=7.XFOU\H1]H01O(<5G&H3'DO>E M0^X7V<5!Z%D_AO"P\(,/?O!/Y'TF6SF\7?'E65G$WCHQR$DYK,P.6E+$%M>I M[U@6S!4&8,?<4CB)KA2W+#\24;(&6R^".:J^:NFL6V6-_H^C8+ME[E>ZLU]_LD#S,QV65S-:;:, M5KT0@UD8 ?T$Q':,9C'I'%I3G+CI/K68-TTKE M^^59B051/[!\V0=Y)5WVIQQXOOYE'/G6D <+7(FYBK&"U95@'7@QE)[+'885 M\1QJ)7(T9BR32MQX=%KPJBU^O;8--E^Y@9Y$P^:N4:N]" T7[#),M7F< MY\JQ7\5JG;+L:9G*GA;_\HO]O9/#[E&''9R=]CH'O4_3>^ _>OR.ZTK!+L?2 M%6'(GW'@-NN**U_@4?ZSC;F[W:ALMW";H],_#R][9QA_.ZUU.\W'_K/MOW$8?O_5.CO?^ M'U!+ 0(4 Q0 ( $V!:%/99O)%2@, *H, 1 " 0 M !C87)A+3(P,C$Q,3 X+GAS9%!+ 0(4 Q0 ( $V!:%-P'HP( 0L .*' M 5 " 7D# !C87)A+3(P,C$Q,3 X7VQA8BYX;6Q02P$" M% ,4 " !-@6A3BC;V]EX' !'60 %0 @ &M#@ 8V%R M82TR,#(Q,3$P.%]P&UL4$L! A0#% @ 38%H4_!#%\?R$@ N&@ M !( ( !/A8 '1M,C$S,C(Q-60Q7SAK+FAT;5!+ 0(4 Q0 M ( $V!:%,^ZM'(E28 ,=A 0 6 " 6 I !T;3(Q,S(R E,35D,5]E>#DY+3$N:'1M4$L%!@ % 4 20$ "E0 $! end